Enable Injections, Inc.

enFuse is a purely mechanical, hands-free wearable injector designed for subcutaneous administration of large-volume (5-50 mL) pharmaceutical and biologic therapeutics, including high-viscosity formulations. It supports self-administration using standard container closures such as syringes, vials, or cartridges, offering patients convenience over intravenous methods.

Headquartered in Cincinnati with in-house design, development, and manufacturing capabilities, Enable Injections has raised over $300 million in funding. The enFuse platform received its first U.S. FDA combination product approval in 2023 and EU MDR CE Mark in 2025. The company partners with biopharma firms like Aptar Digital Health, Sanofi, Incyte, Roche, and Sobi to integrate enFuse with specific therapeutics for clinical trials and commercialization.